Research Analysts’ Weekly Ratings Updates for Climb Bio (CLYM)

Several analysts have recently updated their ratings and price targets for Climb Bio (NASDAQ: CLYM):

• 3/24/2026 – Climb Bio is now covered by B. Riley Financial, Inc.. They set a “buy” rating and a $26.00 price target on the stock.
• 3/23/2026 – Climb Bio was upgraded by B. Riley Financial, Inc. to “strong-buy”.
• 3/17/2026 – Climb Bio is now covered by Truist Financial Corporation. They set a “buy” rating and a $17.00 price target on the stock.
• 3/17/2026 – Climb Bio was upgraded by Truist Financial Corporation to “strong-buy”.
• 3/10/2026 – Climb Bio is now covered by Raymond James Financial, Inc.. They set a “strong-buy” rating and a $25.00 price target on the stock.
• 3/10/2026 – Climb Bio had its price target raised by HC Wainwright from $11.00 to $15.00. They now have a “buy” rating on the stock.
• 3/6/2026 – Climb Bio had its price target raised by Robert W. Baird from $9.00 to $12.00. They now have an “outperform” rating on the stock.
• 3/5/2026 – Climb Bio is now covered by Wedbush. They set an “outperform” rating and a $12.00 price target on the stock.
• 2/13/2026 – Climb Bio is now covered by Piper Sandler. They set an “overweight” rating on the stock.

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.